8-K: Merit Medical Appoints New Chair, Reports Strong Q4 Revenue

Merit Medical Systems, Inc. announced the appointment of F. Ann Millner as Chair of the Board following Fred P. Lampropoulos's resignation and reported preliminary unaudited Q4 2025 revenue growth of 10% to 11% year-over-year.

Summary

• Fred P. Lampropoulos resigned as a director and Chair of the Board, effective January 4, 2026, citing personal reasons, following the conclusion of his employment as Executive Chair and his prior resignation as President and Chief Executive Officer.
• F. Ann Millner, Ed.D., formerly the Lead Independent Director, was appointed Chair of the Board, effective January 5, 2026.
• The Board of Directors voted unanimously to reduce its size from eleven members to ten members, effective January 5, 2026.
• Merit Medical entered into a consulting agreement with Mr. Lampropoulos for a three-month period, starting January 7, 2026, with consulting fees of $250,000 per month.
• Preliminary unaudited revenue for the fourth quarter ended December 31, 2025, is projected to be in the range of approximately $389 million to $395 million.
• This preliminary revenue represents an approximate 10% to 11% increase year-over-year compared to Q4 2024 revenue of $355.158 million.
• Preliminary unaudited constant currency revenue for Q4 2025 is estimated to have increased in the range of approximately 8% to 10% year-over-year.
• The company plans to announce its full financial results for the fourth quarter and year ended December 31, 2025, and issue its fiscal year 2026 guidance on Tuesday, February 24, 2026.

Sentiment

Score: 7

Explanation: The filing presents strong preliminary revenue growth and a smooth leadership transition, with the outgoing founder expressing confidence. While a founder's departure is a notable event, the company explicitly states it's not due to disputes or financial issues, and a consulting agreement is in place. The positive financial performance outweighs the inherent uncertainty of a leadership change.

Positives

• Preliminary unaudited revenue for Q4 2025 is projected to be strong, ranging from $389 million to $395 million, representing a 10% to 11% year-over-year increase.
• Preliminary unaudited constant currency revenue for Q4 2025 also shows robust growth, increasing approximately 8% to 10% year-over-year.
• The company explicitly stated that Fred P. Lampropoulos's resignation was not the result of any dispute or disagreement with management or the Board, nor any matter related to financial reporting, internal controls, operations, policies, or business practices.
• The appointment of F. Ann Millner, an experienced director and former Lead Independent Director, as Chair of the Board ensures continuity and strong governance.
• Merit Medical remains focused on strong execution towards its 'Continued Growth Initiatives' and related financial targets for the three-year period ending December 31, 2026.

Negatives

• The departure of Fred P. Lampropoulos, the company's founder and long-standing leader after 38 years, marks a significant leadership transition.

Risks

• Risks and uncertainties associated with executive succession planning activities and leadership transition.
• Risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed or prospective tariffs, duties or other measures.
• Risks and uncertainties associated with the integration of the C2 CryoBalloon device and related assets acquired from Pentax of America, Inc. in November 2025 and the ability to achieve financial results, product development and other anticipated benefits of such acquisition.
• Risks and uncertainties associated with the integration of the business and operations of Biolife Delaware, L.L.C. acquired in May 2025 and its ability to achieve financial results, product development and other anticipated benefits of such acquisition.
• Effects of the 3.00% Senior Convertible Notes on net income and earnings per share performance.
• Disruptions in the supply chain, manufacturing or sterilization processes.
• U.S. and global political, economic, competitive, reimbursement and regulatory conditions.
• Modification or limitation of, or policies and procedures associated with, governmental or private insurance reimbursement policies.
• Reduced availability of, and price increases associated with, components and other raw materials.
• Increases in transportation expenses.
• Risks relating to potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions.
• Fluctuations in interest or foreign currency exchange rates and inflation.
• Cybersecurity events.
• Government scrutiny and regulation of the medical device industry.
• Difficulties relating to development, testing and regulatory approval, clearance and maintenance of products.
• The safety, efficacy and patient and physician adoption of products.
• The ability to fully enroll and the outcomes of ongoing and future clinical trials and market studies relating to products.
• Litigation and other judicial proceedings affecting Merit.
• Failure to comply with U.S. and foreign laws and regulations.
• Restrictions on liquidity or business operations resulting from debt agreements.
• Infringement of technology or the assertion that technology infringes the rights of other parties.
• Product recalls and product liability claims.
• Potential for significant adverse changes in governing regulations.
• Changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax liabilities which may adversely affect the effective tax rate.
• Termination of relationships with suppliers, or failure of such suppliers to perform.
• Development of new products and technology that could render existing or future products obsolete.
• Market acceptance of new products.
• Failure to comply with applicable environmental laws.
• Changes in key personnel.
• Labor shortages and increases in labor costs.
• Price and product competition.
• Extreme weather events.
• Geopolitical events.

Future Outlook

Merit Medical Systems, Inc. plans to announce its full financial results for the fourth quarter and the year ended December 31, 2025, and issue its fiscal year 2026 guidance after the close of the stock market on Tuesday, February 24, 2026. The company remains focused on strong execution towards achievement of its Continued Growth Initiatives and related financial targets for the three-year period ending December 31, 2026.

Management Comments

• "As I step down after 38 years since founding Merit, I am proud of how far we've come and believe the company is stronger than ever. The management team and the Board are well positioned to guide Merit's talented employees forward. Their commitment to excellence and innovation will further Merit's mission of delivering products that improve lives around the world." (Fred P. Lampropoulos)
• "Fred's vision and leadership have been instrumental in building Merit into the global healthcare company it is today. On behalf of the Board and the entire organization, I want to express our gratitude for his decades of service and commitment to improving patient care. Merit remains focused on strong execution towards achievement of our Continued Growth Initiatives and related financial targets for the three-year period ending December 31, 2026 and delivering value to our customers, employees, and shareholders." (Dr. F. Ann Millner)

Industry Context

The medical device industry continues to see innovation and strategic leadership changes. Merit Medical's preliminary revenue growth of 10-11% year-over-year suggests robust demand for its interventional, diagnostic, and therapeutic products, aligning with broader trends of increasing healthcare technology adoption. The transition of a founder CEO to a consulting role, followed by the appointment of an experienced independent director as Chair, reflects a common corporate governance evolution in mature companies, aiming for continuity while bringing fresh perspectives to strategic oversight.

Management Changes

Corporate Governance

Related Party Transactions

• Merit Medical entered into a consulting agreement with former director and Chair, Fred P. Lampropoulos, for a three-month period, with consulting fees of $250,000 per month, effective January 7, 2026.

Stakeholder Impact

• Shareholders: Potential positive impact from strong preliminary revenue growth and clear succession planning for board leadership. The consulting agreement with the founder ensures continued access to his expertise.
• Employees: The company's continued focus on 'Continued Growth Initiatives' suggests stability and ongoing strategic direction.
• Customers: Continued focus on delivering products that improve lives and strong execution towards growth initiatives implies ongoing product development and service.
• Management: The new Chair's statement of confidence in the management team suggests stability and support for current strategic direction.

Next Steps

• Merit Medical will announce its financial results for the quarter and year ended December 31, 2025, on February 24, 2026.
• The company will issue its fiscal year 2026 guidance on February 24, 2026.
• The company will continue to execute its 'Continued Growth Initiatives' towards financial targets for the three-year period ending December 31, 2026.

Key Dates

Recommendation

The preliminary Q4 2025 revenue growth of 10-11% is strong and indicates healthy operational performance. However, the departure of the founder and long-standing leader, Fred P. Lampropoulos, while stated as amicable and not related to disputes, introduces an element of leadership transition risk. The appointment of an experienced independent director as Chair and the consulting agreement with Mr. Lampropoulos mitigate some of this risk, but the full impact of such a significant change will unfold over time. Investors should hold to observe the company's performance under the new board leadership and await the full Q4 and FY2025 results and 2026 guidance on February 24, 2026, for a more complete picture.

Keywords

Merit Medical Systems, MMSI, Medical Devices, Healthcare Technology, Q4 2025 Revenue, Preliminary Results, Board Chair Appointment, Leadership Transition, Fred P. Lampropoulos, F. Ann Millner, Corporate Governance, Financial Guidance, Interventional Procedures, Diagnostic Procedures, Therapeutic Procedures